+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Primary Biliary Cholangitis (PBC) Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997395
  • Report
  • March 2020
  • Region: Global
  • 110 pages
  • Mordor Intelligence
UP TO OFF
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Allergan Inc.
  • Eli Lilly and Company
  • Endo International plc
  • Glenmark Pharmaceuticals
  • Mylan Inc.
  • Novartis AG
  • MORE
The global primary biliary cholangitis (PBC) market is projected to grow with a CAGR of nearly 10% over the forecast period. The growth is attributed to the increase in cases of primary biliary cholangitis and increasing R&D investment in the development of new therapeutics for the disease. Due to the recurring nature of the disease currently, there are only a few treatment options available for the disease, primarily liver transplantation. Moreover, regenerative and stem cell therapies are at the nascent stage which will drive the market growth of therapeutics over the forecast period. However, the asymptomatic nature of the disease delays diagnosis and treatment, lack of awareness among the population about the disease and stringent regulatory policies are the factors that are anticipated to hamper the market growth.

Key Market Trends

Obeticholic Acid to Grow at Significant Rate
  • Presently, there is no total cure for the disease. But, the liver damage can be delayed using the therapeutics. Ocaliva is a semisynthetic bile acid analogue which is used as a primary drug for the treatment of primary biliary cholangitis.
  • On the other hand, Ursodeoxycholic acid is a secondary bile acid produced by intestinal bacteria. This shows advanced effects on kidney destruction, but a few percentages of the patient shows intolerance to the drug.
  • According to the U.S. Department of Health and Human Services, 65 out of 100,000 women and about 10 of 100,000 men in the United States have primary biliary cholangitis.
  • Moreover, factors such as the increase in R&D investments and presence of robust pipeline in for autoimmune diseases, especially primary biliary cholangitis are anticipated to boost the market growth over the forecast period.
North America to Have Significant Growth

Among the regional segments, North America is projected to have significant market growth owing to well-established healthcare infrastructure, presence of key market players and recent product launches. Moreover, the growing number of patients with the primary biliary cirrhosis and growing demand for the therapeutics is anticipated to fuel the market growth over the forecast period. Ocaliva drug was approved in 2016, in Europe and the United States, and had notable initial sales, however, the recent black box warnings from the regulatory authorities have impacted the usage. There is a tremendous need for the development of new therapeutics, and it is taken up by the market players in the region anticipated to boost the regional growth.

Competitive Landscape

Global primary biliary cholangitis (PBC) therapeutics market is moderately competitive. Market players are focusing on new product launches, product innovations and geographical expansion. The key market players operating in the market include Intercept Pharmaceuticals, Inc., Teva Pharmaceutical, Allergan Inc. and Glenmark Pharmaceuticals among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan Inc.
  • Eli Lilly and Company
  • Endo International plc
  • Glenmark Pharmaceuticals
  • Mylan Inc.
  • Novartis AG
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing R&D For Development of New Drug Therapeutics For Primary Biliary Cholangitis
4.2.2 Growing Burden of Primary Biliary Cholangitis and Liver Related Disorders
4.3 Market Restraints
4.3.1 Stringent Regulatory Policies
4.3.2 Lack of Awareness Regarding Liver Disorders
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Obeticholic Acid
5.1.2 Ursodeoxycholic Acid
5.1.3 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Intercept Pharmaceuticals, Inc.
6.1.2 Teva Pharmaceutical
6.1.3 Mylan Inc.
6.1.4 Allergan Inc.
6.1.5 Glenmark Pharmaceuticals
6.1.6 Eli Lilly and Company
6.1.7 Endo International plc
6.1.8 Novartis AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Intercept Pharmaceuticals, Inc.
  • Teva Pharmaceutical
  • Mylan Inc.
  • Allergan Inc.
  • Glenmark Pharmaceuticals
  • Eli Lilly and Company
  • Endo International plc
  • Novartis AG
Note: Product cover images may vary from those shown
Adroll
adroll